600671.SH
Hangzhou Tian-Mu-Shan Pharmaceutical Enterprise Co., Ltd.
SSE · Healthcare · Drug Manufacturers - General · CN
CNY 18.45
−0.43%Oct 30, 2026, 12:52 UTC
Tianmu Pharmaceutical completed the resumption of production of Compound Fresh Bamboo Juice Oral Liquid, a key OTC product it is developing.
Source:Oct 30, 2026, 12:52 UTC
Tianmu Pharmaceutical reported third-quarter and first-nine-month 2026 results, including revenue of RMB 150 million and attributable net profit of RMB 8.106 million for the first nine months.
Source:Aug 27, 2026, 09:40 UTC
Tianmu Pharmaceutical announced its first-half 2026 results: net profit attributable to shareholders was 6.3022 million yuan, down 38.50% year-on-year.
Source: